New Zealand - English - Medsafe (Medicines Safety Authority)

apotex nz ltd - ropinirole hydrochloride 0.285mg equivalent to to 0.25 mg ropinirole - film coated tablet - 0.25 mg - active: ropinirole hydrochloride 0.285mg equivalent to to 0.25 mg ropinirole excipient: citric acid hyprolose hypromellose lactose macrogol 8000 magnesium stearate titanium dioxide - ropinirole is indicated for the treatment of parkinson's disease. ropinirole is effective as early therapy in patients requiring dopaminergic therapy. in a comparative study, ropinirole was superior to bromocriptine. when these two drugs were administered concomitantly with selegiline there was no difference between them. ropinirole delays the need for initiation of l-dopa therapy. as adjunctive treatment of l-dopa, ropinirole enhances the efficacy of l-dopa, including control of "on-off" fluctuations and "end of dose" effects associated with chronic l-dopa therapy and permits reduction in daily l-dopa dose.

New Zealand - English - Medsafe (Medicines Safety Authority)

accord healthcare nz ltd - ropinirole hydrochloride 0.285mg equivalent to 0.25 mg ropinirole - film coated tablet - 0.25 mg - active: ropinirole hydrochloride 0.285mg equivalent to 0.25 mg ropinirole excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry white 13b58802 - ropaccord tablets is indicated for the treatment of parkinson's disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

teva pharma (new zealand) limited - ropinirole hydrochloride 0.285mg equivalent to 0.25 mg ropinirole;  ;   - film coated tablet - 0.25 mg - active: ropinirole hydrochloride 0.285mg equivalent to 0.25 mg ropinirole     excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry white 85f18378 - arrow - ropinirole is indicated for the treatment of parkinson's disease. ropinirole is effective as early therapy in patients requiring dopaminergic therapy. in a comparative study, ropinirole was superior to bromocriptine. when these two drugs were administered concomitantly with selegiline there was no difference between them. ropinirole delays the need for initiation of l-dopa therapy. as adjunctive treatment of l-dopa, ropinirole enhances the efficacy of l-dopa, including control of "on-off" fluctuations and "end of dose" effects associated with chronic l-dopa therapy and permits reduction in daily l-dopa dose.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - ropinirole hydrochloride 0.285mg equivalent to 0.25 mg ropinirole;   - film coated tablet - 0.25 mg - active: ropinirole hydrochloride 0.285mg equivalent to 0.25 mg ropinirole   excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry white oy-s-9603 - requip is indicated for the treatment of parkinson's disease.

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - ropinirole hydrochloride 0.285mg equivalent to ropinirol 0.25 mg;  ; ropinirole hydrochloride 0.57mg equivalent to ropinirol 0.5 mg; ropinirole hydrochloride 1.14mg equivalent to ropinirol 1 mg - film coated tablet - 0.25mg, 0.5mg & 1mg - active: ropinirole hydrochloride 0.285mg equivalent to ropinirol 0.25 mg   excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry white oy-s-9603 active: ropinirole hydrochloride 0.57mg equivalent to ropinirol 0.5 mg excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry yellow oy-s-22907 active: ropinirole hydrochloride 1.14mg equivalent to ropinirol 1 mg excipient: croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry green 03b21094 - requip is indicated for the treatment of parkinson's disease.

United States - English - NLM (National Library of Medicine)

zydus pharmaceuticals (usa) inc. - ropinirole hydrochloride (unii: d7zd41rzi9) (ropinirole - unii:030pyr8953) - ropinirole 0.25 mg - ropinirole hydrochloride tablets are indicated for the treatment of parkinson's disease. ropinirole hydrochloride tablets are indicated for the treatment of moderate-to-severe primary restless legs syndrome (rls). ropinirole hydrochloride tablets are contraindicated in patients known to have a hypersensitivity/allergic reaction (including urticaria, angioedema, rash, pruritus) to ropinirole or to any of the excipients. risk summary there are no adequate data on the developmental risk associated with the use of ropinirole in pregnant women. in animal studies, ropinirole had adverse effects on development when administered to pregnant rats at doses similar to (neurobehavioral impairment) or greater than (teratogenicity and embryolethality at >36 times) the maximum recommended human dose (mrhd) for parkinson's disease. ropinirole doses associated with teratogenicity and embryolethality in pregnant rats were associated with maternal toxicity. in pregnant rabbits, ropinirole potentiated the teratogenic effects of

United States - English - NLM (National Library of Medicine)

zydus lifesciences limited - ropinirole hydrochloride (unii: d7zd41rzi9) (ropinirole - unii:030pyr8953) - ropinirole 0.25 mg - ropinirole hydrochloride tablets are indicated for the treatment of parkinson's disease. ropinirole hydrochloride tablets are indicated for the treatment of moderate-to-severe primary restless legs syndrome (rls). ropinirole hydrochloride tablets are contraindicated in patients known to have a hypersensitivity/allergic reaction (including urticaria, angioedema, rash, pruritus) to ropinirole or to any of the excipients. risk summary there are no adequate data on the developmental risk associated with the use of ropinirole in pregnant women. in animal studies, ropinirole had adverse effects on development when administered to pregnant rats at doses similar to (neurobehavioral impairment) or greater than (teratogenicity and embryolethality at >36 times) the maximum recommended human dose (mrhd) for parkinson's disease. ropinirole doses associated with teratogenicity and embryolethality in pregnant rats were associated with maternal toxicity. in pregnant rabbits, ropinirole potentiated the teratogenic effects of

United States - English - NLM (National Library of Medicine)

ncs healthcare of ky, inc dba vangard labs - ropinirole hydrochloride (unii: d7zd41rzi9) (ropinirole - unii:030pyr8953) - ropinirole 0.25 mg - ropinirole hydrochloride tablets are indicated for the treatment of the signs and symptoms of idiopathic parkinson's disease. the effectiveness of ropinirole hydrochloride tablets was demonstrated in randomized, controlled trials in patients with early parkinson's disease who were not receiving concomitant l-dopa therapy as well as in patients with advanced disease on concomitant l-dopa (see clinical pharmacology: clinical trials). ropinirole hydrochloride tablets are indicated for the treatment of moderate-to-severe primary restless legs syndrome (rls). key diagnostic criteria for rls are: an urge to move the legs usually accompanied or caused by uncomfortable and unpleasant leg sensations; symptoms begin or worsen during periods of rest or inactivity such as lying or sitting; symptoms are partially or totally relieved by movement such as walking or stretching at least as long as the activity continues; and symptoms are worse or occur only in the evening or night. difficulty falling asleep may frequently be

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - ropinirole hydrochloride (unii: d7zd41rzi9) (ropinirole - unii:030pyr8953) - ropinirole 0.25 mg - ropinirole hydrochloride tablets are indicated for the treatment of the signs and symptoms of idiopathic parkinson's disease. the effectiveness of ropinirole hydrochloride tablets was demonstrated in randomized, controlled trials in patients with early parkinson's disease who were not receiving concomitant l-dopa therapy as well as in patients with advanced disease on concomitant l-dopa (see clinical pharmacology, clinical trials ). ropinirole hydrochloride tablets are indicated for the treatment of moderate-to-severe primary restless legs syndrome (rls). key diagnostic criteria for rls are: an urge to move the legs usually accompanied or caused by uncomfortable and unpleasant leg sensations; symptoms begin or worsen during periods of rest or inactivity such as lying or sitting; symptoms are partially or totally relieved by movement such as walking or stretching at least as long as the activity continues; and symptoms are worse or occur only in the evening or night. difficulty falling asleep may frequently be

United States - English - NLM (National Library of Medicine)

stat rx usa llc - ropinirole hydrochloride (unii: d7zd41rzi9) (ropinirole - unii:030pyr8953) - ropinirole 1 mg - ropinirole hydrochloride tablets are indicated for the treatment of the signs and symptoms of idiopathic parkinson's disease. the effectiveness of ropinirole hydrochloride tablets was demonstrated in randomized, controlled trials in patients with early parkinson's disease who were not receiving concomitant l-dopa therapy as well as in patients with advanced disease on concomitant l-dopa (see clinical pharmacology: clinical trials). ropinirole hydrochloride tablets are indicated for the treatment of moderate-to-severe primary restless legs syndrome (rls). key diagnostic criteria for rls are: an urge to move the legs usually accompanied or caused by uncomfortable and unpleasant leg sensations; symptoms begin or worsen during periods of rest or inactivity such as lying or sitting; symptoms are partially or totally relieved by movement such as walking or stretching at least as long as the activity continues; and symptoms are worse or occur only in the evening or night. difficulty falling asleep may fr